WP-PEP (LRELEDALEQER)
Thrombin exosite-II-binding 12-residue anticoagulant peptide screened from Whitmania pigra hydrolysates (Hua 2025) via computation-guided strategy.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Thrombin exosite-II-binding 12-residue anticoagulant peptide screened from Whitmania pigra hydrolysates (Hua 2025) via computation-guided strategy.
- Evidence level
- Preclinical (animal)
- Drug vs leech
- Synthetic analog
- Safety domains
- Bleeding
Clinical translation limit
WP-PEP's preclinical anticoagulant activity does NOT establish clinical efficacy. No FDA-approved derivative exists; Whitmania pigra is a non-hematophagous TCM leech, not the FDA-cleared K040187 medicinal leech.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 1,456 Da
- Source species
- Whitmania pigra
- Discovered
- 2025 · Hua YT et al.
Biological Targets
- → thrombin exosite II (Arg233, Arg101 binding residues)
Key Citations
- Hua YT et al. (2025), J Pept Sci · PMID 40922112
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.